In summary, we revealed that MAGI2-AS3 was decreased expression in HCC, and it can inhibit HCC progression via the miR-519c-3p/TXNIP axis, which provided insights that MAGI2-AS3 may be the effective target for HCC treatment. This evidence concerns the gene PDS5B and hepatocellular carcinoma.